



RESEARCH PAPER

 OPEN ACCESS 

Adaptation of the emerging pathogenic yeast *Candida auris* to high caspofungin concentrations correlates with cell wall changes

Violeta Lara-Aguilar^a, Cristina Rueda^a, Irene García-Barbazán^a, Sarai Varona^b, Sara Monzón^b, Pilar Jiménez^c, Isabel Cuesta^b, Ángel Zaballos^c, and Óscar Zaragoza^a

^aMycology Reference Laboratory, National Centre for Microbiology, Instituto De Salud Carlos III, Madrid, Spain; ^bBioinformatics Unit, Core Scientific and Technical Units, Instituto De Salud Carlos III, Madrid, Spain; ^cGenomics Unit, Core Scientific and Technical Units, Instituto De Salud Carlos III, Madrid, Spain

ABSTRACT

Candida auris has emerged as a fungal pathogen that causes nosocomial outbreaks worldwide. Diseases caused by this fungus are of concern, due to its reduced susceptibility to several antifungals. *C. auris* exhibits paradoxical growth (PG; defined as growth at high, but not intermediate antifungal concentrations) in the presence of caspofungin (CPF). We have characterized the cellular changes associated with adaptation to CPF. Using EUCAST AFST protocols, all *C. auris* isolates tested showed PG to CPF, although in some isolates it was more prominent. Most isolates also showed a trailing effect (TE) to micafungin and anidulafungin. We identified two *FKS* genes in *C. auris* that encode the echinocandins target, namely β -1,3-glucan synthase. *FKS1* contained the consensus hot-spot (HS) 1 and HS2 sequences. *FKS2* only contained the HS1 region which had a change (F635Y), that has been shown to confer resistance to echinocandins in *C. glabrata*. PG has been characterized in other species, mainly *C. albicans*, where high CPF concentrations induced an increase in chitin, cell volume and aggregation. In *C. auris* CPF only induced a slight accumulation of chitin, and none of the other phenomena. RNAseq experiments demonstrated that CPF induced the expression of genes encoding several GPI-anchored cell wall proteins, membrane proteins required for the stability of the cell wall, chitin synthase and mitogen-activated protein kinases (MAPKs) involved in cell integrity, such as *BCK2*, *HOG1* and *MKC1* (*SLT2*). Our work highlights some of the processes induced in *C. auris* to adapt to echinocandins.

ARTICLE HISTORY

Received 3 December 2020

Revised 15 April 2021

Accepted 30 April 2021


KEYWORDS

Candida auris; trailing effect; paradoxical growth or Eagle effect; echinocandins; *FKS*; chitin; resistance; β -1,3-glucans


INTRODUCTION

In recent years, *Candida auris* has emerged as a multi-resistant pathogenic fungus associated with nosocomial environments, often in intensive care units (ICU) in several countries across five continents [1,2]. Diseases caused by *C. auris* pose a challenge for several reasons including: a) delayed detection due to the available phenotypic and biochemical methods and frequent confusion with other *Candida* species [3,4]; b) its ability to persist in a hospital environment as well as on the surface of medical instruments [2]; c) its ability to form biofilms and transmit from person to person [5,6]; d) its possession of virulence mechanisms and ability to evade the immune response or prevent the attack of neutrophils [7]; and e) its resistance to antifungal agents [6], as well as disinfectants used in daily practice [8].

Candida auris was first isolated in Japan in 2009 from a patient's external ear canal [9]. Since then, this species has emerged almost simultaneously in other regions, including Asia, America, Africa and Europe [2,5,10–12]. The reason why *C. auris* has rapidly become a pathogen of concern in recent years is not known, but it has been suggested that some environmental changes (such as global warming) have favored that this species is becoming a part of our natural microbiota [13,14]. Genetic description of *C. auris* isolates from different geographical origins demonstrates that this species clusters into five different clades [11,12,15,16]. Diseases caused by *C. auris* have been associated with similar risk factors as for other *Candida* species infections, such as extremes of age, the presence of comorbidities, serious surgery, use of catheters and previous antifungal therapy [5,12,17]. However, unlike other *Candida* species, *C. auris* does not appear to effectively colonize the gastrointestinal

CONTACT Óscar Zaragoza  ozaragoza@isciii.es

§Present Address: Laboratory of Reference and Research on Viral Hepatitis, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

 Supplemental data for this article can be accessed [here](#)

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

tract, probably due to its poor growth under anaerobic conditions [11]. Different genomic studies have provided several factors that could be involved in its virulence mechanisms, such as production of lipases, oligopeptides transporters and siderophores [18]. Similarly to other opportunistic fungal pathogens, such as *C. albicans* or *C. glabrata* [19], *C. auris* has been shown to be virulent in mouse models.

Currently, there are four classes of antifungals available for treatment of candidiasis: azoles, polyenes (e.g. amphotericin B and nystatin), echinocandins (CPF caspofungin, MICA micafungin and ANIDU anidulafungin) and flucytosine. However, the treatment of diseases caused by *C. auris* is challenging because of different antifungal susceptibility profiles among clinical isolates and the ability to develop resistance to two or even three classes of antifungal drugs [12,20,21]. In particular, *C. auris* is fully resistant to fluconazole. The use of echinocandins as first-line therapies subject to a sensitivity testing has been recommended [17,22].

Echinocandins are semi-synthetic lipopeptides that present killing activity against *Candida* species, whose mechanism of action consists of noncompetitive inhibition of the Fks1p subunit of the enzyme β -1,3-glucan synthase [23]. Inhibition of this enzyme leads to cell lysis due to osmotic instability. Importantly, β -D-glucan is not present in mammalian cells, so side effects are minimal.

Although echinocandins are effective against most isolates of *Candida* species resistant to other antifungals, an increase in the number of *C. auris* strains with reduced susceptibility to one or more echinocandins has been observed (MIC \geq 4 μ g/mL for ANIDU and MICA; MIC \geq 2 μ g/mL for CPF) [24]. In fact, four hospitals in India have reported an alarming 37% resistance rate to CPF, determined by the microdilution method based on analysis of 102 isolates of *C. auris* [3].

The main mechanism by which *Candida* species have acquired resistance is through amino acid substitutions caused by mutations in two regions of the target gene *FKS1* and *FKS2*, which exhibit high recombination rates and are called hot-spots (HS1 and HS2) [25]. These mutations produce proteins with lower antifungal affinity [25]. So far, only three mutations have been described in *C. auris* isolates resistant to echinocandins, which take place in HS1 of *FKS1*; the substitution of amino acids S652Y and S639P [26,27], as well as the substitution in the same position S639F, equivalent to the mutation in position S645F that is associated with resistance to echinocandins in *C. albicans* [28].

In addition to the presence of mutations conferring resistance, recent studies indicate that *C. auris* has a peculiar sensitivity profile to echinocandins [29]. For

a high number of isolates, echinocandins are unable to totally inhibit yeast growth. In particular, most isolates present paradoxical growth (PG, or Eagle effect) to CPF and exhibit “trailing” effect (TE, also known as residual growth or tolerance) to MICA and ANIDU *in vitro* during the antifungal susceptibility test (AFST) [30–38].

The “Eagle” or PG consists of the growth of yeasts at high concentrations of antifungal, although they remain susceptible to intermediate concentrations. This phenomenon has been observed in around 20–25% of isolates of some *Candida* species, such as *C. albicans* [30,32,39–42]. It has been associated with the activation of alternative pathways, morphological changes and alterations in the cell wall that compensate the defect of β -1,3-D-glucan, with the increase of chitin, causing an alteration in the immune response of the host [31,33,43].

TE is characterized by the absence of total inhibition of yeast growth with increasing concentrations of antifungal drugs, maintaining a residual growth at high drug concentrations. This phenomenon has been observed mainly with *Candida* species and azoles [44]. In this respect, strong trailing may result in the classification of strains as resistant, although clinical implications are not yet fully known.

In this work, we have studied the *in vitro* adaptation mechanisms of *C. auris* to echinocandins. For this purpose, we aimed to characterize the growth of isolates in the presence of caspofungin, micafungin and anidulafungin, and correlate it with possible changes in the cell wall. Finally, we also investigated the cellular changes induced by high caspofungin concentrations by RNAseq.

MATERIALS AND METHODS

Yeast strains and growth conditions

Seven clinical *C. auris* strains (Table 1) and three *C. albicans* isolates with different susceptibility profiles to echinocandins were used: CL-10449 (CalS, susceptible), CL-10432 (CalPG, strong PG in the presence of CPF) and CL-10272 (CalR, resistant strain that harbors the S645P mutation in HS1 of *FKS1*). As quality control strains, we included *C. krusei* ATCC 6258 and *C. parapsilosis* ATCC 22019.

Yeasts were cultured in Sabouraud liquid (Difco™, 0382–17) or Sabouraud agar (Oxoid, CM 0041) at 30°C.

Antifungal susceptibility

In vitro antifungal susceptibility testing (AFST) was carried out according to EUCAST’s standardized yeast methodology using the plate microdilution method [45]. All plates included *C. parapsilosis* ATCC 22019

Table 1. List of strains used in this work.

Species	Strain	Geographical origin	Reference
<i>Candida auris</i>	CL-10838	Spain	MRL
	CL-10825	Spain	MRL
	CL-9998	Spain	MRL
	CL-10836	Spain	MRL
	CL-10958	Spain	MRL
	12272906	Colombia	MRL
	10263755	Colombia	MRL
<i>Candida albicans</i>	KCTC-17810	Korea	MRL
	CL-10432 (CalPG)	Spain	MRL
	CL-10449 (CalS)	Spain	MRL
<i>Candida krusei</i>	CL-10272 (CalR)	Spain	MRL
	ATCC 6258		ATTC
<i>Candida parapsilosis</i>	ATCC 22019		ATTC

MRL: Mycology Reference Laboratory; ATTC: American Type Culture Collection

and *C. krusei* ATCC 6258 strains, as recommended by CLSI and EUCAST for quality.

RPMI-G medium was prepared with RPMI 1640 medium (Merck, Sigma-Aldrich, R-6504) buffered with MOPS (Merck, Sigma-Aldrich, M-1254) at pH 7 and supplemented with 2% glucose (Merck, Sigma-Aldrich, G-8270). Cell density was determined spectrophotometrically and the strains were inoculated at a final concentration of 1 to 5×10^5 yeasts/mL. Antifungal concentration ranges were as follows: CPF (0.03 to 16 $\mu\text{g/mL}$) (Merck, Sigma-Aldrich, SML0425), MICA (0.004 to 2 $\mu\text{g/mL}$) (Molcan Corporation, 208-538-73-2) and ANIDU (0.008 to 4 $\mu\text{g/mL}$) (Molcan Corporation, 166663-25-8). Plates were incubated at 35°C for 24 h in a humid atmosphere, and the optical density (OD) was measured at 530 nm after 24 h of incubation using an EZ Read 400 (Biochrom, Cambridge, UK) microplates reading spectrophotometer. The minimum inhibitory concentration (MIC) was defined as the lowest antifungal concentration that caused a 50% growth inhibition compared to the control wells without antifungal. PG was defined when the yeasts were able to recover growth at high antifungal concentrations but inhibited at intermediate concentrations. TE was described when growth was inhibited by increasing concentrations of the antifungal, but this inhibition was not complete, and above a certain concentration, growth was not affected anymore.

Growth curves

Growth curves were performed using microdilution plates with CPF concentrations between 0.03 to 16 $\mu\text{g/mL}$. Plates were inoculated with 1 to 5×10^5 yeasts/mL and incubated at 35°C in a Multiskan FC spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). Optical densities (ODs) were measured at 540 nm

each hour for 48 h. Results were analyzed using GraphPad Prism software, version 5.0. The lag period was established as the time needed to reach the basal OD and begin exponential growth. The doubling period was determined as the time in which the population doubled the OD, taking into account the logarithmic equation of the line obtained from the growth curves.

DNA sequence analysis of *FKS1* and *FKS2* HS

To sequence the HS regions of the target genes *FKS1* and *FKS2* of *C. auris*, we amplified these genomic regions from CL-10836, CL-10838 and CL-10825 strains by PCR. Briefly, genomic DNA was extracted from individual colonies. Cells were disrupted with zirconia/silica beads (0.5 mm diameter) using FastPrep-24 (MP™, CA, USA) for 3 cycles, alternating 15 s shaking with 15 s on ice. DNA was obtained using phenol-chloroform and precipitated with 0.6x volumes of cold isopropanol. The pellet was washed with 70% ethanol and dissolved in 50 μL of distilled water with RNase (40 $\mu\text{g/mL}$). Finally, DNA was purified using ChromaSPIN+ TE 200 columns (Clontech, 636082). The primers to amplify the HS1 and HS2 regions from *FKS1* and HS1 from *FKS2* were designed from the sequence with access number “MK059973.1” and “XM_029033096.1” available at GenBank, respectively (Table 2) and synthesized by Sigma-100 ENOSYS. To amplify a genomic region containing both HS1 and HS2 from *FKS1*, PCR was performed with primers FKS1-HS1-F and FKS1-HS2-R (0.5 μM) and 25 ng/mL of genomic DNA and employed the following thermal cycles: an initial step of 2 min at 98°C and 30 cycles of 98°C for 30 s, 72°C for 3 min with a final extension step at 72°C for 7 min. A fragment of 2.601 bp was obtained, which was sequenced using the four primers designed for *FKS1* (see Table 2). To amplify the HS1 from *FKS2*, a fragment of 377 bp was obtained by PCR using the same genomic DNA and primers FKS2-HS1-F and FKS2-HS1-R. The PCR cycles were the same as described for *FKS1*, but with an amplification time of 1 min at 72°C.

PCR products were treated with illustra™ ExoProStar™ (GE Healthcare Life Sciences, US77705). Purified PCR fragments were sequenced on both strands using 1 μM HS-F and HS-R primers and the BigDye™ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 4337457) to perform sequence reactions. Sequences were assembled and edited using SeqMan II and EditSeq Lasergene software programs (DNASTar, Madison, WI, USA).

Table 2. Sequence of the primers and probes used in the study.

Gene	Primer or probe	Sense	Sequence (5'-3')	Primer Size (bp)
FKS1	FKS1_HS1_F	Forward	TCTGCCATCTCGAAGTCTGC	20
	FKS1_HS1_R	Reverse	GCGAAATCAACACCTTTGGT	20
	FKS1_HS2_R	Reverse	ACCACCAACGGTCAAGTCTG	20
	FKS1_HS2_F	Forward	CCACGAATCCATTTGTGTG	20
	FKS1_RT ¹ _F	Forward	TGGTAGATTCATCGCCGACA	20
	FKS1_RT ¹ _R	Reverse	GACCACCAGGATGAGACCTT	20
	FKS1 probe		6FAM-TGTACCGCTCATGTTAGCACCA-BHQ1	22
FKS2	FKS2_HS1_F	Forward	AAATGGAAGGGTTCACCTTG	20
	FKS2_HS1_R	Reverse	TCCAAGCGTCCAGATAGAT	20
	FKS2_RT ¹ _F	Forward	TACACCCAGCAACGCAATTT	20
	FKS2_RT ¹ _R	Reverse	GCTGCGATTAAGCTGGGAAA	20
	FKS2 probe		6FAM-CATCTGCGTGAACATTGGCTT-BHQ1	21

¹Used in Real Time PCR and Digital PCR

Estimation of chitin content and cellular volume

To evaluate changes in the cell wall of *C. auris* in response to different concentrations of CPF, chitin content was estimated by staining with Calcofluor White (CFW) (Merck, Sigma-Aldrich, F3543). Cells were inoculated in Sabouraud liquid medium and incubated at 30°C overnight with shaking (150 rpm). Cells were then washed with PBS and a suspension of 0.5 to 2.5×10^5 cells/mL was prepared in RPMI-G. Five mL of these suspensions were incubated with different CPF concentrations (0, 0.06, 0.5 and 8 µg/mL) at 35°C with shaking for 24 h. Next, they were centrifuged at 2,500 rpm for 10 min and washed three times using 1 mL of PBS. Afterward, cells were fixed with 4% paraformaldehyde (Merck, Sigma-Aldrich, P6148) for 40 min at room temperature. The fixed cells were finally washed and suspended in 1 mL of PBS.

Cells were then incubated in PBS containing 1% bovine serum albumin (BSA, Merck, Sigma Aldrich, A4503) for 30 min at 37°C to avoid nonspecific binding. To detect chitin content on the cell wall, cells were incubated for 30 min with 10 µg/mL of CFW at 37°C in the dark. Samples were then washed with PBS and fluorescence was observed with a Leica SP5 confocal. Pictures (8 bits, 256 different gray intensities per pixel) were taken using LAS AF software (Leica Microsystems). The fluorescence intensity was estimated using Image J software (<http://rsb.info.nih.gov/ij>) and expressed as arbitrary units (scale from 0–255).

In addition, cellular volumes from at least 30 cells per sample were calculated by using the spheroid equation $V = \pi/6 b^2 \times a$, where “b” is the length and “a” is the width of the cell.

Time-lapse recording and video processing

Candida auris and *C. albicans* cells were suspended at a final concentration of 0.5 – 2.5×10^5 cells/mL in 96-

well microtitre plates well containing CPF (0.5 and 8 µg/mL) in RPMI-G medium (see above). Plates were placed under a Leica SP5 confocal microscope which had a temperature-regulated chamber adjusted to 35°C. Images were taken with PMT-BF and excitation laser at 561 nm (AOTF at 8%), using a laser speed of 600 Hz. Pictures were taken every 5 min for 16 h using a 10x objective and 2x zoom. The .lif files were processed with ImageJ software and videos in .avi format were generated.

Total RNA extraction in *C. auris*

A total of three samples were analyzed for each condition, each sample was from a different biological replicate obtained in different days. *Candida auris* CL-10836 was incubated in 100 mL of Sabouraud liquid medium overnight at 35°C with shaking (150 rpm). Cells were collected in exponential phase and washed with PBS. Cells were centrifuged at 15,000 g for 5 min and suspended in RPMI-G medium. A suspension of cells was inoculated in two equal fractions to a final concentration of 10^7 cells/mL; one was used as a control without antifungal and the other was incubated with 8 µg/mL of CPF at 35°C with shaking (150 rpm). After 3 h, both aliquots were centrifuged at 12,500 rpm for 5 min and stored at –20°C.

RNA extraction was performed using Trizol (TRI Reagent®, Merck, Sigma-Aldrich, 93289) with some modifications. Cells were disrupted with zirconia/silica beads (0.5 mm diameter) using a FastPrep-24 (MP™, CA, USA) for 4 cycles, alternating 40 s shaking with 1 min on ice. The extract was suspended in 50 µl of Ultra Pure Water and stored at –20°C. RNA concentration and quality was estimated using the Agilent 2100 Bioanalyzer. To eliminate DNA contamination from the RNA, all samples were treated with DNase using the DNA-free™ DNA Removal Kit (Life

Technologies S.A., Ambion, AM1906), according to the manufacturer's instructions.

Comparative gene expression of *FKS1* and *FKS2* using Real Time PCR

Extracted RNA was converted into complementary DNA (cDNA) using iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories, 1708891), according to the manufacturer's instructions. Quantitative RT-qPCR was performed in a LightCycler 480 unit (Roche Diagnostics, Mannheim, Germany). Primer sequences for *FKS1* and *FKS2* are presented in Table 2. A final volume of 20 µl per reaction was prepared as follows: 1x SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, 1725270); 0.5 µM forward and reverse primer (*FKS1* or *FKS2*) and 50 ng of cDNA. The RT-qPCR protocol had an initial step at 95°C for 30 s, followed by 40 cycles of amplification and quantification at 95°C for 30 s and 60°C for 1 min, with a single fluorescence measurement; and a final step at 95°C and continuous fluorescence measurement (melting curves). Real-time PCR efficiencies were estimated as previously described [46].

Absolute quantification of *FKS1* and *FKS2* genes using Digital PCR

Primers designed for RT-qPCR were used in these experiments. Taqman probes targeting *C. auris* *FKS1* and *FKS2* genes were designed using Beacon Designer 7.0 software (Premier Biosoft, Palo Alto, CA) and synthesized by Merck, Sigma-Aldrich (Madrid, Spain). Sequences of primers and probes used in this study are detailed in Table 2. The number of *FKS1* and *FKS2* cDNA molecules was quantified using QuantStudioTM 3D Digital PCR System (Applied Biosystems, A29154). Conditions for digital PCR were as follows: 1x QuantStudio 3D Digital PCR Mastermix v2 (Applied Biosystems, 4482710), 0.4 µM forward and reverse primer (*FKS1* or *FKS2*), 0.2 µM MB probe and 50 ng of cDNA (see above), in a final volume of 14.5 µl. Reactions were placed on a QuantStudioTM 3D Digital PCR 20 K Chip v2 (Applied Biosystems, A26317) automatically using QuantStudioTM 3D Digital PCR Chip Loader (Applied Biosystems, CA, USA), and amplified following thermal cycling conditions recommended by manufacturer's protocol. Applied BiosystemsTM QuantStudioTM 3D AnalysisSuiteTM Cloud Software was used for the analysis of data derived from the QuantStudio 3D Digital PCR instrument.

Analysis of global gene expression using RNAseq

Libraries for RNAseq were prepared from 1 µg of total RNA (see Total RNA extraction in *C. auris*) using the TruSeq Stranded mRNA kit (Illumina, 20019792). Briefly, polyadenylated RNA was purified using oligodT beads, fragmented with divalent cations and converted to ds cDNA. Index adapters were then added and final libraries obtained after PCR. Quality and concentration of the libraries was estimated using Agilent 2100 Bioanalyzer and QuantiFluor[®] RNA System (Promega, E3310). A 4 nM pool containing equimolar fractions from each library was prepared, and 2 × 75 paired-end sequencing was performed in a NextSeq 550 Illumina platform using NextSeq 500/550 Mid Output Kit v2.5 (Illumina, 20024904).

The results were analyzed with a RNA-seq pipeline (<https://github.com/BU-ISCI/rnaseq-nf>) written in Nextflow (<https://www.nextflow.io/>) based on the nf-core (<https://nf-co.re/>) previously written RNA-seq pipeline (<https://github.com/nf-core/rnaseq>). Fastq files containing raw reads were first analyzed for quality using fastQC v0.11.8 [<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>]. Raw reads were trimmed for low quality 3' ends and adapter sequences removal using Trimmomatic v0.38 [47]. The high-quality reads were then aligned against the *C. auris* reference genome GCA_002759435.2_Cand_auris_B8441_V2 using STAR v2.6.1d [48] and alignment quality control was performed using RseQC v3.0.0 22743226. Finally, transcriptome prediction and gene quantification were calculated using Subread's featureCounts package v1.6.4 [49]. Original FastQ files were deposited at the Sequence Reads Archive (SRA, <https://www.ncbi.nlm.nih.gov/sra>) from the NCBI database (temporary Submission ID SUB8665675; BioProject ID PRJNA682422). The BioSample Accession numbers for the samples are SAMN16989163, SAMN16989164 and SAMN16989165 for the control samples (cells incubated in RPMI) and SAMN16989166, SAMN16989167 and SAMN16989168 for the three samples treated with CPF (8 µg/mL).

Many of the genes in *C. auris* are annotated as unknown proteins, but functional homologs can be found for the majority of these genes in the *C. albicans* and *S. cerevisiae* databases. For this reason, we performed an in-house annotation of the B8441 genome. The full list of all the ORFs from *C. auris* was compared in the *C. albicans* genome and a list of the homologs with the corresponding function was obtained. A similar approach was performed with the *S. cerevisiae* database. In this way, a list of all the *C. auris* genes with the corresponding homologs

(when present) in *C. albicans* and *S. cerevisiae* was generated.

To characterize the functional categories of the identified CPF-regulated genes, two different types GO from the *Candida* genome database (candida-genome.org): GO Term finder (cellular function option) and GO Slim Mapper (component option) were used.

Statistics

Differences in chitin content, cellular volume and changes in expression of *FKS* genes were assessed by t-Test using GraphPad software. ANOVA test with Bonferroni correction was used to determine differences in the number of copies of *FKS* genes (digital PCR). To identify differentially expressed genes (DEGs), differential expression analysis was carried out using DESeq2 R/Bioconductor package v1.18.1 [50]. DESeq2 was also used for normalization and results visualization.

RESULTS

Susceptibility profile of *C. auris* strains to echinocandins

The susceptibility profile of seven *C. auris* clinical isolates from different origins was compared with three *C. albicans* isolates that exhibited different susceptibility profiles to echinocandins (susceptible, resistant and paradoxical growth). All *C. auris* isolates exhibited similar PG in the presence of CPF (Figure 1). The CL-10836 strain showed the highest PG (Figure 1g), with an increase in growth of 77% with respect to the MIC. *C. albicans* strain CL-10432 also showed PG growth, being inhibition at intermediate concentrations practically total (Figure 1e). In contrast, growth reduction for all *C. auris* did not exceed 80% than that of the control growth (figure 1f to l). This growth capacity at increasing antifungal concentrations was different from the profile observed in a CaS (Figure 1c, CL-10449) or CaR strain (Figure 1d, CL-10272).

Micafungin and anidulafungin inhibited growth of *C. auris* (Supplemental Figures 1 and 2). However,




Figure 1. Characterization of *Candida* growth in the presence of CPF (0.03–16 µg/mL). *In vitro* susceptibility profile for the seven isolates of *C. auris*. The growth percentage represents the percentage of OD measured at 530 nm.




Figure 2. Expression of *FKS* genes in *C. auris* CL-10836 control cells. Cycle threshold value (Ct) of *FKS1* and *FKS2* genes determined by RT-qPCR (a); Number of cDNA copies per μ L of *FKS1* gene (black bars) and *FKS2* gene (white bars) in control cells without antifungal (control) (b). * $p < 0.001$; statistical analysis was performed using Student's t-test. The data are presented as the mean plus SD of 3 independent experiments.

most isolates showed residual growth (or trailing) at increasing antifungal concentrations (Supplemental Figures 2 and 3). This trailing was not present for any

of the *C. albicans* nor the quality control strains (*C. krusei* and *C. parapsilosis*, Supplemental Figures 2 and 3). Therefore, these results indicated that *C. auris*




Figure 3. Changes in the wall of *C. auris* and *C. albicans* during PG. The images represent *C. auris* cells CL-10836 (a, b, e, f, i and j) and *C. albicans* CL-10432 (b, c, g, h, k and l) in different treatments: control cells (a–d), cells incubated with 0.5 μ g/mL of CPF (e–h) and cells incubated with 8 μ g/mL of CPF (i–l). Chitin was labeled with calcofluor and fluorescence was observed in a SP5 confocal microscope as described in M&M. The scale at the bottom right of the images represents 5 μ m.

has a special adaptation to echinocandins and that this adaptation was different from that observed in resistant strains of *C. albicans*.

Growth curves

To characterize changes in *C. auris* cell growth in response to CPF, growth curves with increasing concentrations of CPF were established. Test strains of *C. albicans* were CalR CL-10272 and CalPG CL-10432. At low CPF concentrations (0.06 µg/mL) both species showed a short lag period of 5 h, as well as an average doubling time similar to the growth control (around 6.5 h for *C. auris* and 4.9 h for *C. albicans*) (Table 3). However, at inhibitory concentrations (0.5 µg/mL) an increase in the lag period and duplication time was observed for both species. *Candida auris* grew slowly, with periods of lag and average doubling times that were 2 and 4.5 times greater than the growth control, respectively (Table 3). However, CalPG (CL10432) was the most affected strain, exhibiting a lag period 5.2 times longer and a doubling time 7.9 times longer than that the growth control (Table 3). No growth effects were found for the CalR strain with 0.5 µg/mL of CPF.

Finally, at high CPF concentrations (8 µg/mL), growth of *C. auris* isolates and CalPG were comparable to the intermediate concentration. The average doubling period for *C. auris* isolates was around 2.3 times greater than that of the growth control, analogous to that observed for *C. albicans*. The lag period was 1.4 and 1.6 times longer than that for the growth control of *C. auris* and *C. albicans*, respectively (Table 3). However, this delay in the lag period did not affect the final growth of *C. auris* cells, as the yeasts achieved a final OD similar to that obtained with the control yeasts not exposed to CPF. As expected, growth of the CalR strain CL-10272 was markedly inhibited with high CPF concentrations (Table 3).

Sequencing of the hot spots of the *C. auris* FKS genes

We next studied whether the adaptation of *C. auris* to echinocandins correlated with changes in the sequence of the target enzyme, β -1,3-glucan synthase. Firstly, a sequence analysis was performed on the genome of *C. auris*, where we identified two *FKS* genes. When the coding protein sequence was analyzed, the Fks1 enzyme gene had sequences of HS1 and HS2 regions. For the gene for the Fks2 enzyme, the HS1 region was detected, but not the HS2 region. For this reason, we designed

primers to sequence the HS1 and HS2 regions of *FKS1* and HS1 of *FKS2*.

The three isolates analyzed (CL-10836, CL-10838 and CL-10825) showed the WT sequence of the reference genomes deposited in the databases. In all cases, the HS1 and HS2 regions from Fks1 had the sequence present in *Candida* susceptible species. Interestingly, in the HS1 from Fks2, we found that *C. auris* exhibited two changes compared to other susceptible species, namely substitutions of F635Y and R641K (Table 4). These changes were found in all reference genomes available in GenBank databases, so we assumed that this was the WT sequence from this species. It is noteworthy that the F635Y substitution has previously been shown to confer resistance to echinocandins in *C. glabrata* [51].

Expression of *FKS* genes in *C. auris*

Since HS1 from Fks2 showed a sequence that could potentially confer resistance to echinocandins, it could be argued that this was the reason of the adaptation of *C. auris* to these antifungals. However, the susceptibility profile observed in *C. auris* differed to the one observed in other resistant isolates from *Candida* species, such as *C. albicans* or *C. glabrata* with mutations in the HS. In these cases, changes in the HS regions result in reduced susceptibility, but not PG or TE (Figure 1). For this reason, the expression of both *FKS* genes was measured to determine the contribution of Fks2 in the adaptation to echinocandins.

RNA was isolated from control cells without antifungal, and gene expression of the *C. auris* *FKS* genes was studied by RT-qPCR and digital PCR. Real-time PCR efficiencies for both genes were >1.95 (data not shown). Using both techniques, RT-qPCR and digital PCR, we found that in *C. auris*, *FKS1* is more expressed than *FKS2*. When we compared the relative expression of both genes by RT-qPCR, *FKS1* was around 35-fold more expressed than *FKS2* (Figure 2a). Similar findings were observed by digital PCR, where the number of cDNA copies of *FKS1* was 32-fold higher than those of *FKS2* (Figure 2b).

Cell wall chitin content in response to CPF

Candida albicans induces several changes to compensate the inhibition of the synthesis of β -1,3-glucans during CPF treatment, which include an increase of chitin in the cell wall [33,52]. To investigate whether adaptation to CPF in *C. auris* was associated with similar changes, the *C. auris* strains CL-10836 and

Table 3. Analysis of growth curves of *C. auris* and *C. albicans* in the presence of CPF. Lag period and doubling time of isolates of *C. auris*, *C. albicans* strain CL-10432 (CalPG) and *C. albicans* strain CL-10272 (CalR) in different concentrations of CPF ($\mu\text{g/mL}$).

Species	Strain	Lag period (h)					Doubling time (h)			
		CPF ($\mu\text{g/mL}$)					CPF ($\mu\text{g/mL}$)			
		0	0.06	0.5	8	0	0.06	0.5	8	
<i>C. auris</i>	12272906	5	5	14	7	6.8	6.8	43.3	13.3	
	10263755	5	5	13	8	6.6	6.2	34	14.2	
	KCTC-17810	5	5	12	10	6.4	5.6	24.8	15.1	
	CL-10838	5	5	7	6	6.5	5.7	42.5	21.7	
	CL-10825	5	5	8	7	7.6	8.4	23	17.5	
	CL-9998	5	5	8	7	6.1	6.7	22.1	13.8	
	CL-10836	5	5	10	7	6.3	6.1	16.3	7.5	
	Average	5	5	10	7	6.5	6.6	29.6	14.8	
SD	0	0	2.5	1.1	0.5	0.9	9.3	3.8		
<i>C. albicans</i>	CL-10432 (CalPG)	5	5	26	8	4.9	4.9	38.7	11.4	
	CL-10272 (CalR)	4	4	4	10	8	8.3	9.7	52.1	

SD, standard deviation

CalPG CL-10432 were studied as they exhibit strong PG.

To estimate the chitin content, we stained the cells with CFW and quantified chitin levels by fluorescence intensity. In the absence of CFW, the fluorescence signal in *C. auris* appeared to be higher than for *C. albicans*, although this difference was not statistically different (Figures 3a, b, c and d; Figure 4). Of note was that the chitin content significantly increased, not only at elevated antifungal concentrations, but also at concentrations below the MIC for both species (at 0.06 $\mu\text{g/mL}$, around 8-fold increase in *C. auris*, and around 30-fold increase in *C. albicans*, compared to the non-treated cells, Figures 3e-l and 4). The increase in chitin levels in response to increasing concentrations of CPF was more pronounced in *C. albicans*, especially between the inhibitory concentration of 0.5 $\mu\text{g/mL}$ and 8 $\mu\text{g/mL}$ (around 30-fold and 60-fold increase at 0.5 and 8 $\mu\text{g/mL}$, respectively, Figures 3 and 4). Surprisingly, even though *C. auris* subinhibitory CPF concentrations (0.06 $\mu\text{g/mL}$) induced chitin synthesis, higher concentrations of CPF did not result in any further increase in chitin content (around 9 and 10-fold increase at 0.5 and 8 $\mu\text{g/mL}$, respectively, Figure 4). These results suggest that survival of this yeast at elevated CPF concentrations was not as dependent on chitin synthesis as for *C. albicans*.

In a previous study, we observed that *C. albicans* cells increase their cellular volume in response to intermediate and high CPF concentrations [33]. Therefore, we investigated if the morphology of *C. auris* was affected by CPF. *Candida auris* had a cellular volume of around 20 μm^3 in basal conditions. After CPF exposure, the cells became more

spherical (Figure 3e and i), but did not have a significantly higher volume (Figure 5a). In comparison, *C. albicans* cells exhibited a higher volume in basal conditions, around 64 μm^3 . Increasing CPF concentrations resulted in the appearance of a new population of larger spherical cells, reaching cellular volumes of up to 530 μm^3 at 8 $\mu\text{g/mL}$ of CPF (Figures 3 and Figures 5b).

Real time visualization of the effect of CPF on *C. auris* morphology

Adaptation of *C. albicans* to high CPF concentrations has been associated with morphological changes typical of a stress response, including increased cell volume and absence of the development of hyphae [33]. Therefore, studies were undertaken in real time to determine if the adaptation of *C. auris* resulted in similar changes. For this purpose, video analysis was undertaken encompassing the period of growth of CalPG CL-10432 and *C. auris* CL-10836 at different CPF concentrations.

In the absence of CPF, CalPG rapidly formed filaments (Figure 6 a-c), which was not evident with *C. auris* (Figure 7 a-c). In agreement with the growth curves, intermediate CPF concentrations caused a marked growth inhibition which was much more pronounced for *C. albicans*, whose cells had an irregular shape, typical of exploded cells (supplemental video 1 and 2, and Figure 6 D-F and 7 D-F). At high CPF concentrations (8 $\mu\text{g/mL}$), whilst CalPG grew, cells did not form hyphae and exhibited a swollen and aggregated phenotype (Figure 6 D-I). In contrast, CPF did not cause any marked effect on *C. auris* growth or

Table 4. Sequencing of *FKS1* hot spot 1 (HS1) and 2 (HS2) and *FKS2* HS1 from *C. auris* isolates. The amino acids highlighted correspond to the differences in HS1 between *FKS1* and *FKS2*.

Hot spot FKS	Nucleotide Sequence	Amino acid sequence
<i>FKS1</i> HS1	TTCTTCTTGACTTTGTCCTTGAGAGATCCT	⁶³⁴ FFLTSLRDP ⁶⁴³
<i>FKS1</i> HS2	GACTGGATTAGACGTTATACCTTGTC	¹³⁵⁰ DWIRRYTLS ¹³⁵⁸
<i>FKS2</i> HS1	TTCTATCTACTCTCTTTGAAAGATCCT	⁵⁶⁹ FYLTSLKDP ⁵⁷⁸

morphology at high CPF concentrations (Figure 7 G-I). These results suggested that the PG of *C. auris* was less affected at elevated CPF concentrations compared to *C. albicans*.

Candida auris gene expression in the presence of CPF

To further investigate the cellular response of *C. auris* CL-10836 to CPF, total gene expression was quantified.




Figure 4. Quantification of the chitin content in the cell wall of *C. auris* CL-10836 and *C. albicans* CL-10432. The results are expressed in arbitrary intensity units. Statistical differences are shown in comparison with control cells (*) and between CPF concentrations of the same strain (#) ($p < 0.05$). The fluorescence of around 30 cells was measured for each condition. The experiment was performed three times on different days, obtaining consistent results, and the results of a representative experiment are shown.




Figure 5. Distribution of cell volumes after incubation with different concentrations of CPF in *C. auris* CL-10836 (a) and *C. albicans* CL-10432 (b). The cellular volume of around 30 cells was measured for each condition and the average value and standard deviation are plotted as bar graph. The experiment was performed three times on different days, obtaining consistent results, and the results of a representative experiment are shown. Asterisks denote statistical difference between the sample and the control non-treated cells ($p < 0.05$, Kruskal–Wallis test).




Figure 6. Changes in morphology and cell growth of *C. albicans* CL-10432. *In vivo* images show untreated cells (a-c), cells incubated with 0.5 $\mu\text{g}/\text{mL}$ CPF (d-f) and cells incubated in the presence of 8 $\mu\text{g}/\text{mL}$ of CPF (g-h) at initial time (a, d and g), 3 h (b, e and h) and 6 h (c, f and i).

RNA from control and CPF treated cells (8 $\mu\text{g}/\text{mL}$) were isolated and subjected to RNAseq using the Illumina platform.

Transcriptome analysis by RNA-Seq was used to compare untreated and treated cells. As shown in the Principal Component Analysis (PCA) plot in [Figure 8a](#), treated samples and non-treated samples grouped separately based on the top 500 differentially expressed genes (DEGs). A total of 278 genes were overexpressed in the presence of CPF (>2 fold, p value<0.05, supplemental table 1). The normalized expression patterns of these 278 genes among the samples are illustrated in [Figure 8b](#), where a clusterization of the treated cells versus untreated cells was observed. Examination of

the function of the corresponding homologs in *C. albicans* and *S. cerevisiae* revealed that a significant proportion of genes encoded proteins related to cell wall. These included structural proteins of cell wall, membrane proteins involved in cell wall stability, enzymes required for the synthesis of the cell wall polysaccharides and MAPK required for cell integrity, cell wall rearrangements and stress response. The three most overexpressed genes after treatment with CPF encoded two GPI-anchored cell wall proteins homologous to *C. albicans*, Gpa31p and Gpa30p, and another cell wall structural mannoprotein homologous to *S. cerevisiae* Cwp1p. Interestingly, several overexpressed genes were involved in chitin synthesis, which is in




Figure 7. Changes in the morphology and cell growth of *C. auris* CL-10836. *In vivo* images show untreated cells (a-c), cells incubated with 0.5 µg/mL of CPF (d-f) and cells incubated in the presence of 8 µg/mL of CPF (g-i) at initial time (A, D and G), 3 h (B, E and H) and 6 h (C, F and I).

agreement with the accumulation of chitin observed by fluorescence after CPF treatment. These included several genes for chitin synthases and enzymes for glucosamine metabolism, which are involved in the synthesis of UDP-N-acetyl glucosamine (precursor of chitin). It was also found that genes encoding for enzymes required for β -1,6-glucan were induced. Furthermore, CPF increased the expression of the *Fks2*-encoding gene by approximately 2-fold compared with control cells, which suggests a mechanism to compensate the inhibition of β -1,3 glucan caused by CPF. No significant differences in expression of the *FKS1* were found. It was also noteworthy to find that three of the genes

that encoded the main MAPK involved in cell wall integrity (*Bck1*, *Hog1* and *Mck1*, known as *Slp2* in *S. cerevisiae*) were overexpressed in the presence of CPF.

To get a general view of the type of genes that exhibited increased expression, we performed a Gene Ontology Term Analysis. From this, a significant enrichment of genes belonging to the following functions was noted: 1) cell wall organization, structure, regulation and biosynthesis, 2) aminosugar, glucosamine and chitin synthesis and 3) RNA Polymerase II related (supplemental table 2). These results confirmed that gene expression changes in response to CPF were




Figure 8. Results of the differential expression analysis. PCA plot of the top 500 DEGs. The PCA scores plot for PC1 and PC2 are shown with points colored by condition (Treatment or Control). The percentage of the total variance explained by each principal component is shown in brackets on each axis (a) and Heatmap plot of the 278 significantly over-expressed genes in CPF treated cells. The relationship between the color and the normalized expression values are indicated in the side bar. Each row represents one of the genes in the list (b).

related to the cell wall structure and organization. Most of the genes described above were categorized in these functions by the GO algorithm. However, there were some genes, such *PGA30* and *PGA31*, that were not found among this list. For this reason, another GO analysis (GO Slim Mapper) was performed with classification of genes according to their cellular component (cell wall, cytoplasm, nucleus, etc.). Each gene family was manually identified that were related to cell wall and chitin synthesis. A list of 54 genes that were components of the cell wall or were related to this structure were identified (supplemental table 3).

In addition, CPF repressed expression of other genes encoding cell wall proteins, such as *Iff4* and *Rbt1* (involved in adhesion), *Pga7*, *Pga45* and *Scw11* (which presents homology to glucanases). Genes encoding chitinases were also significantly repressed (around 2–3 fold) by CPF. One of the most intriguing features was the finding that the most repressed genes by CPF encoded proteins were involved in zinc and iron uptake. To get a non-biased idea of the main families of genes that were repressed by CPF, a further GO Term analysis was performed and this revealed that amongst this set of genes, the main repressed functions were alcohol and ergosterol biosynthesis and metal ion homeostasis (transport into cell, supplemental table 4).

DISCUSSION

Candida auris is a multi-drug resistant yeast and an emerging pathogen worldwide where it is responsible for invasive nosocomial infections that are often associated with high morbidity and mortality [53]. Although use of echinocandins is now recommended for treatment of *C. auris* infections, an increase in isolates with elevated MICs against this class of antifungals is being observed [54]. This microorganism has a particular ability to persist in hospital or medical material and has the ability to form biofilms, where the concentration of antifungal is higher than that of physiological fluids [53,55]. Therefore, the possibility of yeasts surviving treatment raises an additional concern that should be considered in cases of therapeutic failure.

The results obtained in this study indicated that echinocandins had no fungicidal activity against some *C. auris* isolates, where yeast growth was evident at concentrations equal to or higher than the MIC. Specifically, two phenomena have been detected *in vitro* using EUCAST protocol, PG at high CPF concentrations and a TE with MICA and ANIDU. To date, the latter is more frequent among other antifungals, such as azoles [36].

Our work also suggests that the MIC values of CPF, MICA and ANIDU against *C. auris* should be

interpreted with care as they do not completely inhibit the growth of these isolates. In fact, in some studies they may be considered resistant after 48 h of treatment [29]. Therefore, this work may contribute to establishing criteria that help define whether *C. auris* strains with this type of adaptation should be considered *in vitro* as susceptible, intermediate or resistant to echinocandins. As described in [16], the isolates from the geographical origins used in this study (South Korea, Spain and Colombia) cluster in different clades (II, III and IV, respectively), so we argue that our study includes representative isolates from different clades. This suggests that the phenomena shown in this article are not restricted to a specific *C. auris* genotype. However, the same study demonstrated that several clades can also be isolated from the same country. For this reason, we believe that our work should be further extended and include representative isolates from all the five different clades that have been defined within this species [11,12,15,16].

PG occurs more frequently in the presence of echinocandins, especially CPF [36]. *Candida tropicalis* is the species where PG is most frequently observed [36,56]. Studies show that this phenomenon develops in a significant percentage of *C. auris* isolates from different geographical areas [29,57], while in *C. albicans* it occurs in about 6% of strains [36]. This is in agreement with our results, suggesting that it is not an isolated phenomenon for certain strains, but rather a characteristic phenotype of this species.

To date, *Candida* resistance to echinocandins is mainly caused by mutations in the *FKS* genes [57,58]. In our study, all *C. auris* isolates analyzed showed the same sequence in HS and corresponded to the sequence present in the reference genomes. By comparing the sequence of *C. auris* HS with those of other species, two substitutions in *FKS2* HS1 have been identified: F635Y and R641K. Mutations in these positions have been associated with the acquisition of resistance in *Candida* [58,59]. In particular, the change F635Y has been described for *C. glabrata* strains with reduced susceptibility to echinocandins [51]. However, its association with reduced susceptibility of *C. auris* is unknown. The susceptibility profile indicates that the growth of *C. auris* at different CPF concentrations was dissimilar to that observed for *C. albicans* strains that were fully resistant due to mutations in the HS regions. Our comparison of the expression of the *FKS* genes suggests that for *C. auris*, the main β -1,3-glucan synthase activity is encoded by *FKS1*, which contains the consensus HS sequences and is predicted to be fully susceptible to echinocandins. For this reason, we argue

that the F635Y substitution in HS1 from *FKS2* plays a minor role in susceptibility to these antifungals. However, it is important to consider that the presence of this substitution and absence of consensus HS2 sequence in *C. auris FKS2* suggests that the affinity of echinocandins to this isoenzyme is significantly lower. As a consequence, any change in the balance of *FKS1/FKS2* gene expression, which results in a higher contribution of Fks2p in the β -1,3-glucan synthase activity, might translate in a resistant phenotype. In this regard, we found that after CPF treatment, expression of *FKS2* increased around 2-fold, a change not observed in *FKS1* expression, suggesting a compensatory mechanism to avoid the inhibitory effect of the antifungal. For *S. cerevisiae*, *FKS1* is the main gene expressed in glucose and *FKS2* is induced during starvation and in response to pheromones [60]. Additionally, and in agreement with our findings, *FKS2* is also increased in mutants that have a higher release of β -1,3-glucan from the cell wall [61], suggesting that it is regulated to compensate decreases in the amount of this polysaccharide in the cell wall.

The decrease in susceptibility observed in these isolates at high CPF concentrations could more accurately be described as drug tolerance, as would be expected from adaptive cell physiology due to environmental stress. It has been described that *Candida* species can induce tolerance to different antifungal families, such as azoles and echinocandins [38]. In the case of CPF, tolerance mainly involves cell wall rearrangements, such as increase in chitin synthesis. However, growth at high CPF concentrations is still severely impaired as cells cannot filament and typically show the phenotype of enlarged and abnormal cells [33,52,62]. The adaptation mechanisms to high CPF concentrations in *C. auris* have some similarities, but also differences compared with *C. albicans*. Although there was an increase in chitin content in *C. auris* in the presence of CPF, it was not as marked as observed in *C. albicans*. In addition, growth at high CPF concentrations of CalPG is associated with marked morphological changes not observed in *C. auris*. In general, our data led us to suggest two different hypotheses: Firstly, the cell wall structure in *C. auris* was not as dependant on β -1,3-glucans as in *C. albicans*. However, the fact that *C. auris* cells were inhibited by intermediate concentrations of CPF indicates that this cellular component is still important for the viability of the cells, suggesting that PG depends on adaptation mechanisms induced by high echinocandins concentrations. Secondly, an alternative hypothesis is that survival of *C. auris* in the presence of echinocandins requires induction of adaptive mechanisms, but this produces a different phenotype to those described in

C. albicans. The best characterized adaptation mechanisms during PG involve overexpression of genes implicated in cell wall function, signal transduction and vacuole function [58]. Efflux pumps that expel antifungals from cells have been described as an important factor in resistance and biofilm formation [63]. However, in yeasts, these pumps seem to play a role mainly in resistance to azoles, as they have a very low affinity for echinocandins [58], but their role in *C. auris* remains unknown. In our work, we provide evidence of some of the mechanisms involved in *C. auris* adaptation to CPF. We have shown that the most expressed genes in this condition encode cell wall proteins, such as Pga31, Cwp1 and Pga30. *Candida albicans pga1^{-/-}* mutants are hypersensitive to CPF and have a lower chitin level [64]. Furthermore, *PGA31* is repressed by glucose and induced by non-fermentative carbon sources, such as lactate [65]. Pga30 is another GPI-anchored protein, highly homologous to Pga31. Interestingly, Cwp1 encodes a cell wall mannoprotein anchored to β -1,3- and β -1,6-glucans which is present in *S. cerevisiae*, but does not have any homolog in *C. albicans*. Cwp1 localizes at the birth of the bud scar and increases expression in conditions where there is a release of β -1,3-glucan from the cell wall, as happens in *gas1* mutants [61]. *Candida auris* is evolutionary more closely related to *C. albicans* than to *S. cerevisiae* [18], but we identified 28 genes homologous in *C. auris* and *S. cerevisiae* but absent in *C. albicans*, suggesting that these genes come from a common yeast ancestor, but were lost in the evolution of *C. albicans*. The fact that one of the genes most expressed in *C. auris* in response to CPF was absent in *C. albicans* supports the hypothesis that the adaptation mechanisms of these two species to echinocandins are different.

When performing a functional analysis of the genes induced in *C. auris* by CPF we found different categories, some of them related to cell wall structure and synthesis, and others from membrane, extracellular, cytosol, nucleus, cellular bud, polarized growth, and endomembrane system. Even among these other families, many of the genes had functions related to cell wall regulation. In this way, around half of the upregulated genes had already been associated to the cell wall or regulated by CPF treatment. Among them, it was noteworthy that several chitin synthases were significantly upregulated, which is in agreement with the increase in this polysaccharide measured by fluorescence. Accordingly, we also observed increased the expression of genes involved in glucosamine metabolism, which is required for chitin synthesis [66]. Furthermore, genes that encode chitinases were repressed. Globally, the transcriptional regulation of chitin synthases and chitinases provides a validation of

the RNAseq data. We also detected genes that encode MAPK, involved in the integrity of the cell wall and response to different types of stress. Bck1 (MAPKKK) and Mck1 (MAPK) are regulated by Pkc1 [67–70] and activated in response to cell wall stress, inducing, among other phenomena, chitin synthesis [43]. Absence of these kinases results in hyper-susceptibility to CPF [71–73]. Regarding Hog1, although it was originally described as a MAPK required for adaptation to osmotic stress, it has been shown that it can be activated in response to different types of stress [69]. Hog1 has been recently involved in CPF resistance and cell wall structure in *C. auris* [74]. Although the main activation of these proteins occurs by phosphorylation, the fact that there is also an increase in the expression of the corresponding genes supports that they play a key role in CPF adaptation.

Our gene expression analysis indicates that the cell wall reorganization required for adaptation to CPF also involves the reduction of some cell proteins, such as Iff4 and Rbt1 (involved in adhesion), Pga45 and Scw11 (glucanase). An interesting finding was that many genes repressed by CPF were involved in iron and zinc uptake (such as *PRA1*, *ZRT1*, *ZRT2*, *ZRT3*, *SIT1*, *FTR1*, *PGA7* and *HMX1*). We do not have a clear explanation about these findings, but our results warrant future studies to determine whether susceptibility to echinocandins in *C. auris* is influenced by metal homeostasis.

Finally, although it cannot be predicted whether *C. auris* will continue to be a cause of global concern in recent years, its emergence and social alarm created, not only at a hospital level, but also at a social level, justify future studies to characterize the mechanisms of resistance and virulence developed by this yeast.

Acknowledgments

V.L-A participated in this work in the frame of the master of Infectious Diseases and Public Health from the University of Alcalá de Henares (Madrid). I.G-B is funded by a fellowship (PRE2018-083436) from the Spanish Ministry for Science and Innovation. We thank Ana Cecilia Mesa Arango for the gift of *C. auris* strains from Colombia.

Data availability statement

RNAseq data (raw documents) are available at the Sequence Reads Archive (SRA, <https://www.ncbi.nlm.nih.gov/sra>) from the NCBI database (temporary Submission ID SUB8665675; BioProject ID PRJNA682422). The BioSample Accession numbers for the samples are SAMN16989163, SAMN16989164 and SAMN16989165 for the control samples (cells incubated in RPMI) and SAMN16989166, SAMN16989167 and SAMN16989168 for the three samples treated with CPF (8 μ g/mL).

Disclosure of potential conflicts of interest

No potential conflict of interest was reported by the authors.

Funding

This work was funded by grant SAF2017-86192-R from the Ministerio de Ciencia e Innovación, OZ was also sponsored by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/CIII/0004/0003), co-financed by European Development Regional Fund ERDF “A way to achieve Europe”, Operative program Intelligent Growth 2014-2020 and by Red Española de Investigación en Patología Infecciosa (REIPI RD16/CIII/0004/0003).

References

- [1] Jeffery-Smith A, Taori SK, Schelenz S, et al. *Candida auris*: a Review of the Literature [Review]. *Clinical microbiology reviews*. 2018 Jan;31(1):e00029–17.
- [2] Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrobial resistance and infection control*. 2016; 5:35.
- [3] Kathuria S, Singh PK, Sharma C, et al. Multidrug-Resistant *Candida auris* Misidentified as *Candida haemulonii*: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method [Research Support, Non-U.S. Gov't]. *Journal of clinical microbiology*. 2015 Jun;53(6):1823–1830.
- [4] Wattal C, Oberoi JK, Goel N, et al. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory [Evaluation Study]. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology. 2017 May;36(5):807–812.
- [5] Calvo B, Melo AS, Perozo-Mena A, et al. First report of *Candida auris* in America: Clinical and microbiological aspects of 18 episodes of candidemia [Case Reports]. *The Journal of infection*. 2016 Oct;73(4):369–374.
- [6] Chowdhary A, Sharma C, Meis JF. *Candida auris*: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally [Review]. *PLoS pathogens*. 2017 May;13(5):e1006290.
- [7] Johnson CJ, Davis JM, Huttenlocher A, et al. Emerging Fungal Pathogen *Candida auris* Evades Neutrophil Attack [Research Support, N.I.H., Extramural/Research Support, Non-U.S. Gov't]. *mBio*. 2018 Aug 21;9(4):e01403–18.
- [8] Ku TSN, Walraven CJ, Lee SA. *Candida auris*: Disinfectants and Implications for Infection Control [Review]. *Frontiers in microbiology*. 2018; 9:726.
- [9] Satoh K, Makimura K, Hasumi Y, et al. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital [Research Support, Non-U.S. Gov't]. *Microbiology and immunology*. 2009 Jan;53(1):41–4.
- [10] Chowdhary A, Sharma C, Duggal S, et al. New clonal strain of *Candida auris*, Delhi, India [Research Support, Non-U.S. Gov't]. *Emerging infectious diseases*. 2013 Oct;19(10):1670–1673.
- [11] Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses [Multicenter Study]. *Clinical infectious diseases* : an official publication of the Infectious Diseases Society of America. 2017 Jan 15;64(2):134–140.
- [12] Du H, Bing J, Hu T, et al. *Candida auris*: Epidemiology, biology, antifungal resistance, and virulence. *PLoS pathogens*. 2020 Oct;16(10):e1008921.
- [13] Chybowska AD, Childers DS, Farrer RA. Nine Things Genomics Can Tell Us About *Candida auris*. *Front Genet*. 2020; 11:351.
- [14] Casadevall A, Kontoyiannis DP, Robert V. On the Emergence of *Candida auris*: Climate Change, Azoles, Swamps, and Birds. *mBio*. 2019 Jul 23;10(4).
- [15] Chow NA, de Groot T, Badali H, et al. Potential Fifth Clade of *Candida auris*, Iran, 2018. *Emerging infectious diseases*. 2019 Sep;25(9):1780–1781.
- [16] Chow NA, Munoz JF, Gade L, et al. Tracing the Evolutionary History and Global Expansion of *Candida auris* Using Population Genomic Analyses. *mBio*. 2020 Apr 28;11(2).
- [17] Enoch DA, Yang H, Aliyu SH, et al. The Changing Epidemiology of Invasive Fungal Infections [Review]. *Methods Mol Biol*. 2017; 1508:17–65.
- [18] Munoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in *Candida auris* and related emerging species. *Nature communications*. 2018 Dec 17;9(1):5346.
- [19] Fakhim H, Vaezi A, Dannaoui E, et al. Comparative virulence of *Candida auris* with *Candida haemulonii*, *Candida glabrata* and *Candida albicans* in a murine model. *Mycoses*. 2018 Jun;61(6):377–382.
- [20] Chowdhary A, Anil Kumar V, Sharma C, et al. Multidrug-resistant endemic clonal strain of *Candida auris* in India [Research Support, Non-U.S. Gov't]. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology. 2014 Jun;33(6):919–926.
- [21] Sharma C, Kumar N, Pandey R, et al. Whole genome sequencing of emerging multidrug resistant *Candida auris* isolates in India demonstrates low genetic variation. *New microbes and new infections*. 2016 Sep;13:77–82.
- [22] Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients [Practice Guideline Research Support, Non-U.S. Gov't]. *Clinical microbiology and infection* : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012 Dec;18 Suppl 7:19–37.
- [23] Denning DW. Echinocandins and pneumocandins—a new antifungal class with a novel mode of action

- [Review]. *The Journal of antimicrobial chemotherapy*. 1997 Nov;40(5):611-4.
- [24] Lockhart SR, Berkow EL, Chow N, et al. *Candida auris* for the clinical microbiology laboratory: Not your grandfather's *Candida* species. *Clinical microbiology newsletter*. 2017 Jul 1;39(13):99-103.
- [25] Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical *Candida* sp. isolates [Clinical Trial]. *Antimicrobial agents and chemotherapy*. 2005 Aug;49(8):3264-3273.
- [26] Rhodes J, Abdolrasouli A, Farrer RA, et al. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen *Candida auris*. *Emerging microbes & infections*. 2018 Mar 29;7(1):43.
- [27] Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of *Candida auris*. *Diagnostic microbiology and infectious disease*. 2018 Mar;90(3):196-197.
- [28] Chowdhary A, Prakash A, Sharma C, et al. A multi-centre study of antifungal susceptibility patterns among 350 *Candida auris* isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance [Multicenter Study Research Support, Non-U.S. Gov't]. *The Journal of antimicrobial chemotherapy*. 2018 Apr 1;73(4):891-899.
- [29] Ruiz-Gaitan A, Martinez H, Moret AM, et al. Detection and treatment of *Candida auris* in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients [Research Support, Non-U.S. Gov't]. *Expert review of anti-infective therapy*. 2019 Apr;17(4):295-305.
- [30] Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against *Candida albicans* at high drug concentrations. *Antimicrobial agents and chemotherapy*. 2004 Sep;48(9):3407-3411.
- [31] Stevens DA, Ichinomiya M, Koshi Y, et al. Escape of *Candida* from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. *Antimicrobial agents and chemotherapy*. 2006 Sep;50(9):3160-3161.
- [32] Bayegan S, Majoros L, Kardos G, et al. In vivo studies with a *Candida tropicalis* isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin [Research Support, Non-U.S. Gov't]. *J Microbiol*. 2010 Apr;48(2):170-173.
- [33] Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of *Candida albicans* in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence [Research Support, Non-U.S. Gov't]. *Antimicrobial agents and chemotherapy*. 2014; 58(2):1071-83.
- [34] Lee MK, Williams LE, Warnock DW, et al. Drug resistance genes and trailing growth in *Candida albicans* isolates [Research Support, Non-U.S. Gov't]. *The Journal of antimicrobial chemotherapy*. 2004 Feb;53(2):217-224.
- [35] Dornelas-Ribeiro M, Pinheiro EO, Guerra C, et al. Cellular characterisation of *Candida tropicalis* presenting fluconazole-related trailing growth. *Memorias do Instituto Oswaldo Cruz*. 2012 Feb;107(1):31-38.
- [36] Rueda C, Puig-Asensio M, Guinea J, et al. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2017 Jan;23(1):49.e1-49.e8.
- [37] Rosenberg A, Ene IV, Bibi M, et al. Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. *Nature communications*. 2018 Jun 25;9(1):2470.
- [38] Berman J, Krysan DJ. Drug resistance and tolerance in fungi. *Nat Rev Microbiol*. 2020 Jun; 18(6):319-331.
- [39] Holt SL, Drew RH. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections [Review]. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists*. 2011 Jul 1; 68(13):1207-1220.
- [40] Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed *Candida albicans* biofilms determined by time-kill studies [Comparative Study]. *Antimicrobial agents and chemotherapy*. 2002 Nov;46(11):3634-3636.
- [41] Chamilos G, Lewis RE, Albert N, et al. Paradoxical effect of Echinocandins across *Candida* species in vitro: evidence for echinocandin-specific and *Candida* species-related differences. *Antimicrobial agents and chemotherapy*. 2007 Jun;51(6):2257-2259.
- [42] Fleischhacker M, Radecke C, Schulz B, et al. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of *Candida albicans* and *C. dubliniensis*. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2008 Feb;27(2):127-31.
- [43] Munro CA, Selvaggingi S, de Bruijn I, et al. The PKC, HOG and Ca²⁺ signalling pathways co-ordinately regulate chitin synthesis in *Candida albicans*. *Molecular microbiology*. 2007 Mar;63(5):1399-413.
- [44] Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream *Candida* isolates in the United States. *Antimicrobial agents and chemotherapy*. 2003 Oct;47(10):3149-3154.
- [45] Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on isavuconazole breakpoints for *Aspergillus*, itraconazole breakpoints for *Candida* and updates for the antifungal susceptibility testing method documents. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2016 Jun;22(6):(571):e1-4.
- [46] Li QQ, Skinner J, Bennett JE. Evaluation of reference genes for real-time quantitative PCR studies in *Candida glabrata* following azole treatment. *BMC Mol Biol*. 2012 Jun 29;13:22.
- [47] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014 Aug 1;30(15):2114-2120.
- [48] Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013 Jan 1;29(1):15-21.

- [49] Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*. 2014 Apr 1;30(7):923–930.
- [50] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014; 15(12):550.
- [51] Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among *Candida glabrata* isolates from U.S. population-based surveillance [Research Support, Non-U.S. Gov't]. *Antimicrobial agents and chemotherapy*. 2010 Dec;54(12):5042–5047.
- [52] Bizerra FC, Melo AS, Katchburian E, et al. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different *Candida* species [Research Support, Non-U.S. Gov't]. *Antimicrobial agents and chemotherapy*. 2011 Jan;55(1):302–310.
- [53] Schwartz IS, Smith SW, Dingle TC. Something wicked this way comes: What health care providers need to know about *Candida auris*. Canada communicable disease report = Relevé des maladies transmissibles au Canada. 2018 Nov 1;44(11):271–276.
- [54] Pristov KE, Ghannoum MA. Resistance of *Candida* to azoles and echinocandins worldwide [Review]. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2019 Jul;25(7):792–798.
- [55] Alfouzan W, Dhar R, Albarrag A, et al. The emerging pathogen *Candida auris*: A focus on the Middle-Eastern countries [Review]. *Journal of infection and public health*. 2019 Jul - Aug;12(4):451–459.
- [56] Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different *Candida* species. *Antimicrobial agents and chemotherapy*. 2007 Sep;51(9):3081–3088.
- [57] Kordalewska M, Lee A, Park S, et al. Understanding Echinocandin Resistance in the Emerging Pathogen *Candida auris* [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. *Antimicrobial agents and chemotherapy*. 2018 Jun;62(60).
- [58] Perlin DS. Resistance to echinocandin-class antifungal drugs [Review]. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*. 2007 Jun;10(3):121–130.
- [59] Arendrup MC, Patterson TF. Multidrug-Resistant *Candida*: Epidemiology, Molecular Mechanisms, and Treatment [Review Research Support, Non-U.S. Gov't]. *The Journal of infectious diseases*. 2017 Aug 15;216(suppl_3):S445–S451.
- [60] Mazur P, Morin N, Baginsky W, et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. *Molecular and cellular biology*. 1995 Oct;15(10):5671–5681.
- [61] Ram AF, Kapteyn JC, Montijn RC, et al. Loss of the plasma membrane-bound protein Gas1p in *Saccharomyces cerevisiae* results in the release of beta1,3-glucan into the medium and induces a compensation mechanism to ensure cell wall integrity. *Journal of bacteriology*. 1998 Mar;180(6):1418–1424.
- [62] Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance [Research Support, Non-U.S. Gov't]. *Fungal genetics and biology : FG & B*. 2010 Feb;47(2):117–126.
- [63] Kean R, Delaney C, Sherry L, et al. Transcriptome Assembly and Profiling of *Candida auris* Reveals Novel Insights into Biofilm-Mediated Resistance [Research Support, Non-U.S. Gov't]. *mSphere*. 2018 Jul 11;3(4):e00334–18.
- [64] Plaine A, Walker L, Da Costa G, et al. Functional analysis of *Candida albicans* GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. *Fungal genetics and biology : FG & B*. 2008 Oct;45(10):1404–1414.
- [65] Ene IV, Heilmann CJ, Sorgo AG, et al. Carbon source-induced reprogramming of the cell wall proteome and secretome modulates the adherence and drug resistance of the fungal pathogen *Candida albicans*. *Proteomics*. 2012 Nov; 12(21):3164–3179.
- [66] Merzendorfer H. The cellular basis of chitin synthesis in fungi and insects: common principles and differences. *European journal of cell biology*. 2011 Sep;90(9):759–769.
- [67] Navarro-Garcia F, Sanchez M, Pla J, et al. Functional characterization of the MKC1 gene of *Candida albicans*, which encodes a mitogen-activated protein kinase homolog related to cell integrity. *Molecular and cellular biology*. 1995 Apr;15(4):2197–206.
- [68] Navarro-Garcia F, Alonso-Monge R, Rico H, et al. A role for the MAP kinase gene MKC1 in cell wall construction and morphological transitions in *Candida albicans*. *Microbiology*. 1998 Feb;144 (Pt 2):411–424.
- [69] Monge RA, Roman E, Nombela C, et al. The MAP kinase signal transduction network in *Candida albicans*. *Microbiology*. 2006 Apr;152(Pt 4):905–912.
- [70] Levin DE. Cell wall integrity signaling in *Saccharomyces cerevisiae*. *Microbiology and molecular biology reviews : MMBR*. 2005 Jun;69(2):262–91.
- [71] Wiederhold NP, Kontoyiannis DP, Prince RA, et al. Attenuation of the activity of caspofungin at high concentrations against *Candida albicans*: possible role of cell wall integrity and calcineurin pathways. *Antimicrobial agents and chemotherapy*. 2005 Dec;49(12):5146–5148.
- [72] Caplan T, Polvi EJ, Xie JL, et al. Functional Genomic Screening Reveals Core Modulators of Echinocandin Stress Responses in *Candida albicans*. *Cell reports*. 2018 May 22;23(8):2292–2298.
- [73] Blankenship JR, Fanning S, Hamaker JJ, et al. An extensive circuitry for cell wall regulation in *Candida albicans*. *PLoS pathogens*. 2010 Feb 5;6(2):e1000752.
- [74] Shivarathri R, Jenull S, Stoiber A, et al. The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of *Candida auris*. *mSphere*. 2020 Oct 14;5(5).